An improved genetic system for bioengineering buoyant gas vesicle nanoparticles from Haloarchaea

Shiladitya DasSarma1*, Ram Karan1, Priya DasSarma1, Susan Barnes1, Folasade Ekulona1 and Barbara Smith2

Abstract

Background: Gas vesicles are hollow, buoyant organelles bounded by a thin and extremely stable protein membrane. They are coded by a cluster of gvp genes in the halophilic archaeon, *Halobacterium* sp. NRC-1. Using an expression vector containing the entire gvp gene cluster, gas vesicle nanoparticles (GVNPs) have been successfully bioengineered for antigen display by constructing gene fusions between the gvpC gene and coding sequences from bacterial and viral pathogens.

Results: To improve and streamline the genetic system for bioengineering of GVNPs, we first constructed a strain of *Halobacterium* sp. NRC-1 deleted solely for the gvpC gene. The deleted strain contained smaller, more spindle-shaped nanoparticles observable by transmission electron microscopy, confirming a shape-determining role for GvpC in gas vesicle biogenesis. Next, we constructed expression plasmids containing N-terminal coding portions or the complete gvpC gene. After introducing the expression plasmids into the *Halobacterium* sp. NRC-1 ΔgvpC strain, GvpC protein and variants were localized to the GVNPs by Western blotting analysis and their effects on increasing the size and shape of nanoparticles established by electron microscopy. Finally, a synthetic gene coding for *Gaussia princeps* luciferase was fused to the gvpC gene fragments on expression plasmids, resulting in an enzymatically active GvpC-luciferase fusion protein bound to the buoyant nanoparticles from *Halobacterium*.

Conclusion: GvpC protein and its N-terminal fragments expressed from plasmid constructs complemented a *Halobacterium* sp. NRC-1 ΔgvpC strain and bound to buoyant GVNPs. Fusion of the luciferase reporter gene from *Gaussia princeps* to the gvpC gene derivatives in expression plasmids produced GVNPs with enzymatically active luciferase bound. These results establish a significantly improved genetic system for displaying foreign proteins on *Halobacterium* gas vesicles and extend the bioengineering potential of these novel nanoparticles to catalytically active enzymes.

Keywords: Vaccine, Halophiles, Archaea, Luciferase

Background

Buoyant gas vesicles are prokaryotic organelles that are widely distributed among bacterial and archaeal microorganisms and constitute protein nanoparticles (GVNPs) that may be engineered for biotechnological applications [1-3]. These organelles naturally promote flotation and increase the availability of light and oxygen to many aquatic microorganisms, especially those with photosynthetic or phototrophic capabilities. Water is excluded from the interior, a property that is thought to be a consequence of the hydrophobicity of the interior surface of the proteinaceous membrane. While the exact protein composition of the membrane has been difficult to ascertain due to its extreme stability against solubilization, production of these structures is easily scaled-up and they are simple to purify by hypotonic lysis of the host and concentrate by flotation, enhancing their intrinsic value for biotechnological applications [4,5].

Genetic analysis established the importance of a gene cluster (gvpMLKIHGFEDACNO) for gas vesicle formation in large plasmids of extremely halophilic Archaea.
(Haloarchaea) (Figure 1A) [6-10]. In Halobacterium sp. NRC-1, the gene cluster was found on a 191 kb plasmid, pNRC100, with transcription of gvpACNO oriented rightward, transcription of gvpDEFGHIJKLMNOPLM oriented leftward, and divergent promoters located in the 201 bp gvpA-D intergenic region. Mutants constructed with interruptions in each of the gvp genes by a kanamycin cassette (κ) exhibited a partially or completely gas vesicle-deficient phenotype, indicating that all of the gvp genes are necessary for wild-type gas vesicle formation [11]. This genetic system utilized the natural gas vesicle-deficient mutant strain SD109, with a complete deletion of the gvp gene cluster, and pFM104d, a large (18.9 kbp) Halobacterium-E. coli shuttle plasmid containing the entire 8.9 kbp gvp gene cluster [4,5,11-14].

The protein composition of gas vesicle nanoparticles has been studied primarily by Western blotting analysis using antisera directed against individual gvp gene products [15]. Initially, only GvpA and GvpC proteins were found [8], but further analysis showed the presence of five additional proteins, GvpF, GvpG, GvpJ, GvpL, and GvpM [15]. GvpA, J, and M constitute a small family of proteins (Pfam 741) likely involved in gas vesicle membrane formation, while GvpF and L are coiled-coil proteins (Pfam 6386) with self-associative properties thought to be important for nucleation or growth of the nanoparticles [9,15]. Most of these proteins (GvpA, GvpC, GvpF, GvpJ, and GvpL) were also identified in a recent proteomic study [16]. In genome sequencing studies, genes corresponding to these same proteins were also found in other gas vesicle-forming microbes [17]. An exception was the gvpC gene, which was reported only in the haloarchaeal and cyanobacterial gas vesicle producers.

In Halobacterium sp. NRC-1, the gvpC gene encodes a hydrophilic protein with a predicted molecular weight of 42,391 and a highly acidic pI of only 3.57 [8,9]. In this haloarchaeon, the GvpC protein sequence contains 8 imperfect repeats and an extremely acidic stretch located near the C-terminus. The slight similarity of the haloarchaeal repeats to the repeats in the cyanobacteria suggested that the GvpC proteins play similar roles in both haloarchaea and cyanobacteria [18]. In the cyanobacterium, Anabaena flos-aquae, GvpC has been shown to serve a strengthening role in gas vesicles [19], while in Halobacterium sp. NRC-1, insertion mutations in the gvpC gene generated vesicles with altered shape and size [11]. These findings suggested that GvpC proteins facilitate gas vesicles’ growth and enhance stability in strains which produce them.

The potential value of GvpC protein for bioengineering floating GVNPs was established during mutagenesis of the gvp gene cluster from Halobacterium sp. NRC-1. A gvpC::κ insertion mutant was found to produce primarily spindle-shaped gas vesicles with smaller than wild-type size (Figure 1B & C) and excision of most of the κ insert resulted in the production of vesicles with a peptide fused to GvpC protein that was antigenically displayed and immunologically accessible on the surface [7,11]. Further studies with SIV and chlamydial proteins have shown that bioengineered GVNPs may be used for antigen display and elicit both humoral and cellular responses in mice [4,5,20-22].

The genetic system currently in use for bioengineering of gas vesicle nanoparticles is technically challenging due to the large size and complexity of the gvp gene cluster [7,8]. In order to facilitate bioengineering of nanoparticles, we constructed a new Halobacterium sp. NRC-1 derived host strain and a series of smaller, more versatile plasmid expression vectors. The work documented in this report establishes a significantly improved genetic system for expression of GvpC-fusion proteins, including an active luciferase enzyme from Gaussia princeps [23].

Results

Construction of a Halobacterium ΔgvpC strain and gvpC expression vectors

In order to improve the genetic system for bioengineering of GVNPs [7,8], our first goal was the construction of a gvpC deletion strain, via the ura3-based gene deletion method for Halobacterium sp. NRC-1 [24,25].
Approximately 500-bp flanking regions of \textit{gvpC}, including the first and last few codons of \textit{gvpC}, were cloned into the suicide vector, pBB400 [26], and the resulting plasmid, pBB400\textit{ΔgvpC}, was used to transform \textit{Halobacterium} sp. NRC-1\textit{Δura3}. After selecting sequentially for integration and excision (see Methods), the resulting \textit{Halobacterium} sp. NRC-1\textit{Δura3ΔgvpC} deletion strain (referred henceforth as \textit{ΔgvpC} deletion strain) (Figure 1A) showed a partially gas vesicle-deficient phenotype with small, largely spindle-shaped gas vesicles, similar to that reported for a \textit{gvpC::x} insertion mutant (cf. Figure 1B and C).

To further develop the expression system and test for complementation of the \textit{ΔgvpC} plasmid, we constructed a \textit{gvpC} expression vector series (Figure 2). As the backbone, we used pMC2, an expression plasmid with the high-level cold-inducible \textit{cspD2} promoter, and the ability for replication and selection in both \textit{E. coli} and \textit{Halobacterium}, recently constructed for investigation of a \textit{β}-galactosidase protein from a related haloarchaeon [27]. The \textit{β}-galactosidase gene was excised and replaced with an adapter containing a start codon, a hexahistidine-tag (His-tag), and unique restriction sites for insertion of the foreign genes, resulting in the plasmid pARK (Table 1). A series of PCR amplified \textit{gvpC} gene fragments were then inserted into the unique \textit{AflII} and \textit{AvrII} sites in the adapter region of pARK to construct the pARK-C plasmid series containing various regions of \textit{gvpC} (Figure 2).

**Figure 2 Structure of pARK-C plasmid series used for expression of \textit{gvpC} fragments in \textit{Halobacterium} sp. NRC-1 and \textit{ΔgvpC} strains.** Location and transcriptional orientation of \textit{bla} (pink), \textit{β}-lactamase, for ampicillin resistance; \textit{mev} (black), HMG-CoA reductase for mevinolin resistance; \textit{C1-C4}, \textit{gvpC} segments (blue), and \textit{rep} (green), the \textit{Halobacterium} pGRB replicase gene are shown. Position of the temperature-induced \textit{cspD2} promoter (labeled \textit{Pcs} \(\rightarrow\)), His-tag (red box), and \textit{KpnI}, \textit{NdeI}, \textit{AflII}, \textit{AvrII}, and \textit{BamHI} restriction sites are indicated.

**Engineering of the \textit{gvpC} gene and expression of \textit{GvpC} fragments**

To determine the effect of GvpC length on production and bioengineering of GVNPs, we transformed each member of the pARK-C plasmid series coding N-terminal regions of GvpC into the \textit{ΔgvpC} strain. pARK-C1 contained 130 amino acids of GvpC, pARK-C2 contained 200 amino acids, pARK-C3 contained 280 amino acids, and pARK-C4 plasmid and the wild-type strain contained the complete 382 amino acid GvpC sequence (Figure 3). When the phenotype of the \textit{ΔgvpC} (pARK-C) transformants were compared to the parental \textit{ΔgvpC} and \textit{Δura3} strains, increasing opacity resulting from increasing gas vesicle content was observed in the following order: \textit{ΔgvpC} < \textit{ΔgvpC} (pARK-C1) < \textit{ΔgvpC} (pARK-C2) < \textit{ΔgvpC} (pARK-C3) = \textit{ΔgvpC} (pARK-C4) = \textit{Δura3} (Figure 4, cf. panels A-E, respectively). These findings indicated lower quantities of gas vesicle formation in strains expressing smaller fragments of GvpC and higher quantities in strains expressing larger GvpC fragments or the complete GvpC protein.

To examine the morphology of GVNPs in \textit{ΔgvpC} and derivative \textit{ΔgvpC} (pARK-C series) strains, we treated cells to hypotonic conditions for lysis and purified nanoparticles by centrifugally accelerated flotation (see Methods). The vesicle preparations were spread for electron microscopy and stained with uranyl acetate, and observed as either spindle-shaped or cylindrical-shaped structures. A representative number of GVNPs were measured, confirming that nanoparticles from the parental \textit{ΔgvpC} strain were smaller and more spindle-shaped, as previously observed for the \textit{gvpC::x} mutant, compared to the parental \textit{Δura3} strain. The mean length and width of GVNPs (blue and pink bars, respectively, in Figure 5) were proportional to the size of \textit{gvpC} gene fragment in pARK-C1, C2, and C3 (386–432 nm lengths and 163–202 nm widths), and were intermediate compared to the \textit{ΔgvpC} (344 and 158 nm, respectively) and \textit{Δura3} (458 and 256 nm, respectively) strains. Expression of larger GvpC proteins generally resulted in production of longer and wider gas vesicles.

Western blotting analysis was used to localize GvpC protein and N-terminal fragments expressed from the pARK-C plasmid series in \textit{ΔgvpC} transformants. For this analysis, confluent lawns of cells were grown and lysed by hypotonic lysis. Gas vesicle nanoparticles were collected after low-speed centrifugally accelerated flotation and electrophoresed on SDS-polyacrylamide gels. After transfer, rabbit antisera directed against either the His-tag incorporated at the N-terminal region of GvpC (Figure 6), or a synthetic GvpC peptide (data not shown), were used in Western blotting analysis. The Western blots showed GvpC proteins of expected sizes (N-terminal fragments and full-length GvpC) localized to cell lysates (Figure 6,
Table 1 Strains and plasmids used in this study

| Strain/plasmid | Characteristics | Source or reference |
|----------------|-----------------|---------------------|
| *Halobacterium* sp. strain NRC-1 | Sequenced wild-type strain | Laboratory collection [28] |
| *Halobacterium* sp. strain SD109 | Strain NRC-1 deleted for the *gvp* gene cluster of pNRC100 | Laboratory collection [13] |
| *Halobacterium* sp. strain NRC-1 Δ*ura*3 | Strain NRC-1 Δ*ura*3 coding orotidine-5′-monophosphate | Laboratory collection [24-27] |
| *Halobacterium* sp. strain NRC-1 Δ*ura*3 Δ*gvpC* | Strain NRC-1 Δ*ura*3 deleted for the *gvpC* gene | This study |
| pFM104*gvpC*·κ1 | *Halobacterium*-E. coli shuttle plasmid containing entire *gvp* gene cluster with κ insertion in the *gvpC* gene | Laboratory collection [11] |
| pBB400 | Suicide plasmid capable of replication in *E. coli* but not *Halobacterium*, containing the *ura*3 gene | Laboratory collection [26] |
| pBB400 Δ*gvpC* | pBB400 plasmid containing *gvpC* gene-flanking regions for deletion construction | This study |
| pMC2 | *Halobacterium* expression vector with *cspD2* promoter and *Halorubrum lacusprofundi* β-galactosidase gene | Laboratory collection [27] |
| pARK | *Halobacterium* sp. NRC-1 expression vector with *cspD2* promoter and adapter containing a start codon, His-tag, and restriction sites for insertion of the *gvpC* gene fragments | This study |
| pARK-C1 | pARK derivative with *gvpC* gene C1 fragment | This study |
| pARK-C2 | pARK derivative with *gvpC* gene C2 fragment | This study |
| pARK-C3 | pARK derivative with *gvpC* gene C3 fragment | This study |
| pARK-C4 | pARK derivative with *gvpC* complete gene (C4) | This study |
| pDRK | *Halobacterium* sp. NRC-1 expression vector with *gvpA* promoter and adapter containing a start codon, His-tag, and restriction sites used for insertion of the *gvpC* gene fragments | This study |
| pDRK-C1-L | pDRK derivative containing *gvpC* gene C1 fragment fused to codon-optimized *Gaussia princeps* luciferase gene | This study |
| pDRK-C2-L | pDRK derivative containing *gvpC* gene C2 fragment fused to codon-optimized *Gaussia princeps* luciferase gene | This study |
| pDRK-C3-L | pDRK derivative containing *gvpC* gene C3 fragment fused to codon-optimized *Gaussia princeps* luciferase gene | This study |
| pDRK-C4-L | pDRK derivative containing *gvpC* complete gene (C4) fused to codon-optimized *Gaussia princeps* luciferase gene | This study |

**Figure 3** GvpC protein sequence and engineering sites. The amino acid sequence of GvpC of *Halobacterium* sp. NRC-1 is shown with conserved residues (vertical bars) in the eight imperfect repeats. The GvpC segments used in this study are labeled C1, C2, C3 and C4 at the C-terminal end. The position of the κ insertion in the *gvpC* mutant is labeled ‘κ’. 

DasSarma et al. BMC Biotechnology 2013, 13:112
http://www.biomedcentral.com/1472-6750/13/112
arrows, lanes 2–5) and floating gas vesicle nanoparticles (Figure 6, arrows, lanes 7–10). As previously reported for the GvpC protein, the apparent protein sizes were significantly larger than predicted from molecular weight standards, due to its high acidity [8,15].

Luciferase expression and display on gas vesicles

In order to determine whether GVNPs produced in the ΔgvpC strain can be bioengineered to display foreign proteins, we expressed a synthetic luciferase gene from the marine copepod Gaussia princeps fused to the gvpC gene or its N-terminal fragments [23]. Codons in the synthetic luciferase gene were optimized to reflect usage in Halobacterium sp. NRC-1 [29] and the gene was inserted into the pARK-C plasmid series via an engineered AflI site to produce GvpC-luciferase gene fusions (Figure 7). In order to increase the level of expression, the cspD2 promoter was replaced by the stronger gvpA promoter [9,10,30], recently used to bioengineer extremely radiation resistant derivatives of Halobacterium sp. NRC-1 [31], via the KpnI and NdeI sites (see also Figure 2 and Table 1). Each member of the constructed plasmid series, named pDRK-C1-L to pDRK-C4-L (Figure 7), was then transformed into both wild-type NRC-1 and ΔgvpC strains, transformants were grown as lawns on agar plates and lysed hypotonically, and the GVNPs purified by centrifugally accelerated flotation. To determine whether luciferase was bound to the floating GVNPs, chemiluminescence activity was compared between the subnatant and the floating GVNPs fraction. The results showed that GvpC-luciferase fusion protein was bound to GVNPs and was enzymatically active (Figure 8). Higher levels of activity were observed for the fusion proteins with longer GvpC-fragments or the entire GvpC protein (C3 and C4) compared to the shorter fragments (C1 and C2) (cf. C and D versus A and B in Figure 8).

Interestingly, when members of the pDRK-C-L plasmid series were transformed into Halobacterium sp. NRC-1, which contains a wild-type gvpC gene, nanoparticles containing engineered GvpC-luciferase proteins were also detectable by luciferase activity (Figure 8, pink bars) and Western blotting assays (data not shown). Although higher levels of luciferase activity were observed bound to floating gas vesicle nanoparticles in the ΔgvpC (pDRK-C1-L to C4-L) strains compared to the NRC-1 (pDRK-C1-L to C4-L) strains, luciferase activity was clearly measurable in nanoparticles in the transformed wild-type strain (Figure 8). Moreover, the wild-type GvpC protein was also detected bound to GVNPs in the NRC-1 (pDRK-C1-L to C4-L) strains (data not shown), indicating that two different GvpC forms may be simultaneously bound to the nanoparticles. These results extend the possible biotechnological uses of GVNPs to other applications requiring nanoparticle-bound enzymes and multivalency.

Discussion

We have established an improved genetic system for bioengineering of GVNPs in the model halophilic archaeon, Halobacterium sp. NRC-1. A strain deleted for the gvpC gene and plasmid vectors containing highly active promoters for producing GvpC-fusion proteins were constructed. The system was tested by expressing the entire
gvpC gene, N-terminal portions of gvpC gene fragments, and GvpC-luciferase fusion proteins, all of which bound to the buoyant nanoparticles. The improved genetic engineering system provides the opportunity for insertion of multiple foreign sequences and the potential for production of GVNPs displaying multiple antigens. The work reported here represents a significant step forward in demonstrating the bioengineering capabilities of GVNPs, including their application to antigen display and vaccine development.

The current work has capitalized on the Halobacterium sp. NRC-1 genetic system and recently constructed expression plasmids [25-27,31]. These biotechnological tools have been used to overexpress, purify, and characterize a polyextremophilic β-galactosidase enzyme from an Arctic haloarchaeon, and bioengineer resistance of haloarchaea to ionizing radiation by overexpression of a mammalian-type RPA protein [27,31]. The constructed expression plasmids (pARK and pDRK) contain the high-copy number Halobacterium sp. pGRB miniplasmid for replication and the mevinolin resistance gene for selection in haloarchaea, as well as the plasmid pUC18 vector for replication and selection in the E. coli host. The pARK expression plasmids contain the cspD2 promoter while the pDRK expression plasmids contain the gvpA promoter. Both of these promoters were reported to drive expression of genes inducible under cold temperatures [30]. The pARK and pDRK plasmids were tailored for expression of GvpC fusion proteins and represent convenient vectors for production of bioengineered GVNPs.

Our GVPN-bioengineering and expression system exploits genetic properties of the Halobacterium sp. NRC-1ΔgvpC deletion strain and recombinant capabilities of
the gvpC gene from *Halobacterium* sp. NRC-1 pNRC100 plasmid [8,9]. The ΔgvpC deletion strain, constructed using our *ura3*-deletion method [24,25], contained gas vesicles with smaller, more spindle-shaped vesicles observable by transmission electron microscopy. This finding is consistent with earlier observations suggesting a key role for GvpC protein in shape determination of gas vesicles in haloarchaea [11,32]. As larger GvpC protein variants were supplied via expression plasmids, we observed generally longer and wider vesicles, suggesting that the nanoparticles were increasingly strengthened. Similar results were also obtained for some cyanobacteria, where a strengthening role for the GvpC protein was reported [19,33]. In one study, *A. flos-aqua* GvpC protein produced in *E. coli* could bind and strengthen the structures after native GvpC protein had been removed by urea treatment. GvpC genes have been reported in most if not all gas vesicle-containing haloarchaea and cyanobacteria, indicating that the protein may serve similar functions in these two groups of aquatic microorganisms. However, gvpC is reportedly absent in other *gvp*-containing species, a finding suggesting that it may not be absolutely essential for biosynthesis of gas vesicles [1,15].

An interesting feature of the GvpC protein is the presence of internal repeats (8 in *Halobacterium* sp. NRC-1) [9]. Our results show that even a small subset of these repeats in truncated variants of GvpC proteins is sufficient to permit binding to GVNP. In the pARK-C1 construct, only 3 copies are present, while in pARK-C2, there are 5. Both of these plasmids produced proteins that bound to the vesicles. The longer GvpC variants produced from pARK-C3 and C4 (7 or 8 repeat copies, respectively), complemented production of the nanoparticles considerably better than the smaller GvpC proteins, based on both colony phenotype and vesicle morphology. Similar conclusions were previously reported for *A. flos-aqua* GvpC protein variants containing three or four repeats (out of 5 in the full-length protein) in *in vitro* experiments [34]. In this cyanobacterial system, GvpC depleted vesicles had their strength better restored with proteins containing larger numbers of repeats. In *Halobacterium* sp. NRC-1, the presence of a highly acidic C-terminal region suggests a further role for this feature in stabilizing gas vesicles, likely reflecting the high salinity found in the cytoplasm.

We used a synthetic *Gaussia princeps* luciferase gene to further assess the binding of GvpC fusion proteins to gas vesicles. Initially, we found that the luciferase protein was active when produced in *Halobacterium* via expression vectors alone (our unpublished results) or as a fusion with the GvpC fragments or full-length protein, demonstrating that the marine enzyme was capable of adopting an active structure even after exposure to the hypersaline cytoplasm of *Halobacterium*. Further investigation showed that the GvpC-luciferase fusion proteins were bound to buoyant gas vesicles, confirming that the enzyme is likely displayed on the surface of nanoparticles. Although antigenic proteins and protein fragments have been previously found to be displayed on gas vesicles, these findings now show that an enzyme may also decorate the nanoparticles while retaining its catalytic activity. Moreover, when two different gvpC genes (wild-type and shortened/fused to luciferase) were present, we found that both GvpC forms were bound to the nanoparticles. These results extend the possible biotechnological uses of GVNP to applications requiring multivalency.

All together, our results provide improved genetic and plasmid resources for engineering of GVNP for biotechnological applications. The original system described required the incorporation of target genes into a large plasmid containing the entire gvp gene cluster, pFM104d, and a natural mutant strain deleted for the gene cluster, SD109 [7,8,11-13,35]. The newly described system utilizes the much smaller and more versatile plasmid series, pARK and pDRK, containing a relatively small portion of the *gvp* gene region. The new system allows more facile cloning of genes of interest into the smaller expression vectors and replacement of only a single deleted gene (ΔgvpC) in the gvp gene cluster. These features will greatly facilitate expression of foreign proteins in GVNP, including antigenic proteins from pathogenic microorganisms for vaccine development.

**Conclusions**

Gas vesicle nanoparticles (GVNP) in the halophilic archaea, *Halobacterium* sp. NRC-1, are successfully being used for antigen display and vaccine development. The genetic tools for bioengineering GVNP have now been greatly improved through construction of a *Halobacterium* strain deleted for the gvpC gene and smaller plasmids for expression of foreign proteins fused to GvpC proteins. The utility of the improved system has been demonstrated by expression of an active *Gaussia princeps* luciferase enzyme fused to GvpC and bound to buoyant gas vesicles. These results establish a significantly improved genetic system for displaying foreign proteins on GVNP and extend the bioengineering potential of these novel nanoparticles to catalytically active enzymes.

**Methods**

**Culturing and nanoparticle preparation**

*Halobacterium* strains used for this study (Table 1) included NRC-1, the wild-type (ATCC 700922/JCM11081) [28], SD109, with deletion of the entire gas vesicle gene cluster [13,35], SD109 (pFM104gvpC::κ), with insertions of a kanamycin (κ) cassette in the gvpC gene [11],
NRC-1Δura3 [24-26] for gene knockouts, and NRC-1Δura3ΔgvpC constructed in this study. These strains were grown in CM+ media, as previously described, with the addition of mevinolin (20 μg/ml) (generously provided by Merck, Sharp, and Dohme, Rahway, NJ) when transformed with expression plasmids [26,27].

For preparation of nanoparticles, lawns of Halobacterium cells were collected by washing with 5 ml of PBS solution [137 mM NaCl, 2.7 mM KCl, 10 mM sodium phosphate dibasic, and 2 mM potassium phosphate monobasic (pH 7.4)] containing 1.0 mM MgSO4. Ten μg/ml of DNase I (Roche Diagnostics, Indianapolis, IN) was added and the cell lysate suspension was incubated for 3 hours at 37°C. Lysates were centrifuged at 60 x g overnight in a swinging bucket rotor using a Jouan CR412 centrifuge (Thermo Scientific, Rockford, IL) to accelerate flotation of the gas-filled nanoparticles. Next, intact buoyant nanoparticles were carefully collected into a clean tube and resuspended in PBS solution, floated by overnight centrifugation, as above, and re-collected. The flotation procedure described above was repeated until a milky white suspension of GVNPs was obtained.

For preparation of whole cell extracts, liquid cultures of Halobacterium strains were grown in an illuminated Innova 44 incubator shaker (New Brunswick Scientific, Enfield, CT) at 42°C with shaking at 220 rpm. Ten ml of cultures (OD 1.2 at 600 nm) were harvested by centrifugation (8000 rpm × 10 min at 4°C) in a Sorvall RC-5B centrifuge. Pellets were resuspended in 0.5 ml of sterile distilled water containing freshly prepared 1 mM phenylmethylsulfonyl fluoride (Sigma Corporation, St. Louis, MO), 10 μg/ml DNase I was added, and the lysates incubated at 37°C for 30 minutes and dialyzed against 4 liters of distilled water at 4°C overnight. Protein concentrations were determined by the Bradford dye (Bio-Rad Laboratories, Hercules, CA) binding method [36] using bovine serum albumin (BSA, Sigma Corporation) as a standard.

**Construction of Halobacterium ΔgvpC strain**

Approximately 500 bp regions flanking gvpC were amplified by crossover PCR (using primers shown in Table 2).

### Table 2 Oligonucleotides used in this study

| Oligonucleotide | 5’-3’ sequence | Use |
|-----------------|----------------|-----|
| gvpCdel1F       | CGGAAGCGTTTATTACTCTCTCCAGTCGATG | gvpC deletion construction |
| gvpCdel1R       | GCGGGCGATCATCTCTGGGCTCTGGGCGTACTGTGACAAGCTAT | |
| gvpCdel3F       | GACGAGGATGACTCGCCCGGGCGGGCGTATGAAAAAGTAG | |
| gvpCdel3R       | CGGAACTGACTCTGGTGTAGACCATGCGGGGCTT | |
| gvpA-Ndel       | CTCAAGGTATACCAACTGACCTAAT | Amplification of gvpA promoter |
| gvpA-Arl      | ACTCTGACTCTACCTCTCTCGAGT | gvpC gene segment amplification |
| gvpC-F1AlliGvpC-F | GTTGTGGTTAAGAGGACTGACACAGACAAA | |
| gvpC-C1RArvKgvpC | CGCGTAGGGTGGTGGTGACATCTCTCTGT | |
| gvpC-C2RArvKgvpC | CTGCTAGGGCCTGTAGTCGACAGCTTC | |
| gvpC-C3RArvKgvpC | GTGGTTCGCTTCGCGCCGTCGAC | |
| gvpC-C4RArvKgvpC | AGACCTAGGGTGTGGTTTATCCCGGCG | |
| gvpC-His-adapter F | CGTCTCCATATGACACCAACCACACACACACCTAAGGGCTCTACCTAGGAGGCTTTGGAATC | His-tag adapter for gvpC and antigen fusion expression plasmid construction |
| gvpC-His-adapter R | GATGACCTGCTCTACCTGAGTTAGGCTTTAAGGGTGGTGTTGTTGTTGTTGTTGTTGGTGCATATGAGACG | |
| pKJ-cspD2F      | GCTGGACTGCCTTCTTCGTG | Sequencing of promoters and inserts in pARK and pDRK series plasmids |
| pKJ-BzmH1-I3′160R | GTACTCACCGCTTATCAG | Sequencing across gvpC deletion |
| Universal F 20mer | GTTGAACACAGGACAGCTTAC | Sequencing and determination of luciferase gene orientation |
| Universal R 20mer | CAGAGAAACAGCTTATCAG | |
| Luci Int R      | GGGTTGGCAGAGCTGAGG | |

The resulting amplified crossover PCR fragment was cloned using flanking HindIII sites incorporated in the primers, into the HindIII site of pBB400 (Table 1) [26]. The resulting plasmid, pBB400ΔgvpC, deleted 359/382 codons of the internal portion of the gvpC gene, but retained the first and last seven codons of gvpC as well as seven additional codons in the crossover region. The final construct was sequenced to verify correctness of the inserted PCR fragment and transformed into Halobacterium sp. NRC-1Δura3 using the PEG-EDTA method [37].

pBB400ΔgvpC transformants were selected by plating on CM+ media lacking uracil (HURA), colonies picked and grown in liquid HURA media, and genomic DNA extracted, as previously described [26,37]. Integrant candidates were screened by PCR using the flanking primers.
and genomic DNA as template, and integrants were plated on CM+ plates containing 250 μg/ml 5-fluorouracil (5-FOA) (Toronto Research Chemicals, North York, Canada). Excisant colonies were picked and grown in liquid CM+ media containing 5-FOA, genomic DNA was extracted, and PCR reactions were used to screen for knockout mutants using primers flanking the gvpC gene (Table 2).

Construction of the pARK and pDRK expression plasmids
For construction of the Halobacterium sp. pARK and pDRK expression plasmids, pMC2 expression plasmid was used as the backbone [26,27]. The β-galactosidase gene was excised and replaced with an adapter (see Table 2) containing a start codon, hexahistidine-tag (His-tag), and AvrII, AflII, and AfeII restriction sites. The C1-C4 GvpC fragments were PCR amplified and inserted via the AvrII and AflII sites, and the synthetic Gaussia princeps luciferase gene (LifeTechnologies, Grand Island, NY) was inserted via the AfeI site [23]. The promoter region was replaced via the KpnI and NdeI sites. The constructs were validated by DNA sequencing.

Electron microscopy
For thin-sectioning, cells were fixed in 3% glutaraldehyde-20% NaCl, postfixed in 2% OsO4-20% NaCl for 4 hours, rinsed with 20% NaCl, stained with 5% uranyl acetate in 20% NaCl-20% acetone for 1 hour, and then dehydrated by immersion in a series of isotonic acetone solutions. Samples were then embedded in Spurr medium which was polymerized at 70°C for 8 hours [38]. Thin sections of 600 Å (60 nm) were examined on copper grids stained with lead [39].

For negative staining, purified nanoparticles were adsorbed to glow discharged 400 mesh carbon coated parlodion copper grids for 30 seconds. Grids were then rinsed in distilled deionized water, 3 times for 30 seconds each. Nanoparticles were negatively stained two times for 30 seconds each in 1% uranyl acetate with 0.04% tylose. Grids were blotted with Whatman #1 filter paper and samples imaged on a Hitachi 7600 TEM at 80 kV. Images were captured with an AMT CCD (1 K × 1 K) camera at 8,000× and 30,000× magnifications. Fifty representative gas vesicle nanoparticles from each strain were measured and average values and standard deviations calculated.

Western blotting analysis
The methods used were similar to those previously described [15]. Briefly, cell lysates containing 50 μg of protein or purified gas vesicle nanoparticle preparations containing 2 μg of protein were electrophoresed on 12% polyacrylamide-SDS gels, for 90 minutes at 100 volts using a Bio-Rad vertical gel electrophoresis unit. Proteins were transferred to 0.45 μm Immobilon-P polyvinylidene difluoride (PVDF) membranes (Millipore Corp., Boston, MA) for 1 hour at 100 volts using a Bio-Rad gel blotter. The membranes were washed twice for 5 minutes with TBS buffer [20 mM Tris–HCl (pH 7.6), 137 mM NaCl], blocked for 1 hour with 5% BSA in TBS buffer, incubated overnight at 4°C with affinity column purified rabbit GvpC antibodies (Thermo Scientific) diluted 1:500 [15] or rabbit anti-His-tag antibody (Cell Signaling Technology, Beverly, MA) diluted 1:750. Membranes were then washed 5 times each for 5 minutes with TBS buffer containing 0.1% Tween 20, and incubated with goat anti-rabbit secondary antibodies labeled with alkaline phosphatase (Sigma Corporation), diluted (1:2500) in a solution containing 5% BSA in TBS buffer. For detection of the protein bands, the membrane was incubated in 1-Step NBT/BCIP Substrate (Thermo Scientific) according to the manufacturer’s specification.

Luciferase activity
Whole cell lysates or purified gas vesicle nanoparticles prepared as described above were assayed for Gaussia princeps luciferase activity using the Glow Assay system (Thermo Scientific) according to the manufacturer’s specification. Assays were conducted in 96-well plates using a SpectraMax M5 luminometer (Molecular Devices, Sunnyvale, CA). Induction was calculated in relative light units of the treated sample/average relative light units of the untreated samples.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
SD designed the study and wrote the manuscript. RK conducted Western and protein analysis and carried out cloning and molecular biology, PD assisted with manuscript preparation, bioinformatics, cloning and molecular biology, and gas vesicle microscopy, SB assisted with molecular biology and gas vesicle microscopic analysis, FE assisted with microbiology and gas vesicle microscopic analysis, and BS conducted the electron microscopy. All authors read and approved the final manuscript.

Acknowledgements
This work was supported by Bill & Melinda Gates Foundation grant OPP1061509 and National Institutes of Health grant R03 AI107634. We thank Mr. Abish Regmi and Ms. Heather McDaniel for expert experimental assistance and Dr. Sook Chung for generously providing the luminometer for luciferase assays.

Author details
1Institute of Marine and Environmental Technology and Department of Microbiology and Immunology, University of Maryland School of Medicine, 701 E Pratt Street, Baltimore, MD 21202, USA. 2Johns Hopkins School of Medicine Microscope Facility, Baltimore, MD 21205, USA.

Received: 4 November 2013 Accepted: 17 December 2013 Published: 21 December 2013

References
1. Shivley JM, Cannon GC, Heinhorst S, Bryant DA, DasSarma S, Bazyliński D, Preiss J, Steinbüchel A, Docampo R, Dahl C: Bacterial and archaeal inclusions. In Encyclopedia of life sciences. Chichester: John Wiley & Sons Ltd; 2011.
DasSarma et al. BMC Biotechnology 2013, 13:112
http://www.biomedcentral.com/1472-6750/13/112

2. DasSarma P, Coker JA, Huse Y, DasSarma S: Halophiles, industrial applications. In Encyclopedia of industrial biotechnology: bioprocess, bioseparation, and cell technology. Edited by Flickinger MC. New Jersey: John Wiley & Sons, Inc: 2010: 43.

3. Cai L, Zhao D, Hou J, Wu J, Cai S, DasSarma P, Xiang H: Cellular and organellar membrane-associated proteins in haloarchaea: perspectives on the physiological significance and biotechnological applications. Sci China Life Sci 2012, 55:404–414.

4. Stuart ES, Sremac M, Morshed F, DasSarma S: Antigen presentation using novel particulate organelles from halophilic archaea. J Bacteriol 2001, 88:119–128.

5. Stuart ES, Morshed F, Sremac M, DasSarma S: Cassette-based presentation of SI-V epitopes with recombinant gas vesicles from halophilic archaea. J Bacteriol 2004, 114:225–237.

6. DasSarma S: Mechanisms of genetic variability in Halobacterium halobium: the purple membrane and gas vesicle mutations. Can J Microbiol 1989, 35:65–72.

7. DasSarma S, Arora P: Genetic analysis of gas vesicle gene cluster in haloarchaea. FEMS Microbiol Lett 1997, 153:1–10.

8. Halladay JT, Jones KG, Lin F, MacDonald AB, DasSarma S: The rightward gas vesicle operon in Halobacterium plastid plasmid pNRC100: identification of the gvpA and gvpC genes products by use of antibody probes and genetic analysis of the region downstream of gvpC. J Bacteriol 1993, 175:6894–692.

9. Jones KG, Young DC, DasSarma S: Structure and organization of the gas vesicle gene cluster on the Halobacterium halobium plastid plasmid pNRC100. Gene 1991, 102:1017–1022.

10. DasSarma S, Damerval T, Tandeau de Marsac N: A plasmid-encoded gas vesicle protein gene in a halophilic archaeabacterium. Mol Microbiol 1987, 13:365–370.

11. DasSarma S, Arora P, Lin F, Molinari E, Yin LR: Wild-type gas vesicle formation requires at least ten genes in the gvp gene cluster of Halobacterium halobium plastid plasmid pNRC100. J Bacteriol 1994, 176:7646–7653.

12. Halladay JT, Ng WL, DasSarma S: Genetic transformation of a halophilic archaeabacterium with a gas vesicle gene cluster restores its ability to float. Gene 1992, 119:131–136.

13. Ng WL, Arora P, DasSarma S: Large deletions in class III gas vesicle deficient mutants of Halobacterium halobium. Syst Appl Microbiol 1994, 16:560–568.

14. DasSarma SL, Capes MD, DasSarma P, DasSarma S: HaloWeb: the haloarchaeal genomes database. Saline Syst 2010, 6:12.

15. Shukla HD, DasSarma S: Complexity of gas vesicle biogenesis in Halobacterium sp. strain NRC-1: identification of five new proteins. J Bacteriol 2004, 186:3182–3186.

16. Chu LJ, Chen MC, Setter J, Tsai YS, Yang H, Fang X, Teng YS, Shaffer SA, Taylor GR, van Halder GD, Goodlett DR, Ng WL: New structural proteins of Halobacterium salinarum gas vesicle revealed by comparative proteomics analysis. J Proteome Res 2011, 10:1170–1178.

17. van Keulen G, Hopwood DA, Dijkstra P, Savers RG: Gas vesicles in actinomycetes: old buoys in novel habitats? Trends Microbiol 2005, 13:350–354.

18. Alboyd D, Castets AM, De Marsac NT: The gas vesicle gene (gvp) cluster of the cyanobacterium Pseudanabaena sp. strain PCC 6901. DNA Seq 2001, 12:337–344.

19. Hayes PK, Buchholz B, Walsby AE: Gas vesicles are strengthened by the outer-surface protein, GvpC. Arch Microbiol 1992, 157:229–234.

20. Sremac M, Stuart ES: Recombinant gas vesicles from Halobacterium sp. displaying SI-V peptides demonstrate biotechnology potential as a pathogen peptide delivery vehicle. BMC Biotechnol 2008, 8:99.

21. Sremac M, Stuart ES: StVim Tat, Rev, and Nef1: functional characteristics of T-GV internalization on isotypes, cytokines, and intracellular degradation. BMC Biotechnol 2010, 10:54.

22. Childs TS, Webley WC: In vitro assessment of halobacterial gas vesicles as a Chlamydia vacuum delivery and release system. Vaccine 2012, 30:5942–5948.

23. Verhaegent M, Christopoulos TR: Recombinant Gausso luciferase. Overexpression, purification, and analytical application of a bioluminescent reporter for DNA hybridization. Anal Chem 2003, 74:4378–4385.

24. Peck RF, DasSarma S, Krebs MP: Homologous gene knockout in the archaeon Halobacterium salinarum with uni3 as a counterselectable marker. Mol Microbiol 2000, 35:667–676.

25. Wang G, Kennedy SP, Fasludeen S, Rensing C, DasSarma S: Arsenic resistance in Halobacterium sp. strain NRC-1 examined by using an improved gene knockout system. J Bacteriol 2004, 186:3187–3194.

26. Bergquist BR, Müller JA, DasSarma P, DasSarma S: Genetic systems for halophilic archaea. In Methods in microbiology. Volume 35th edition. Edited by Oren A, Rainey F. New York, NY: Elsevier/Academic Press; 2006:649–680.

27. Karan R, Capes MD, DasSarma P, DasSarma S: Cloning, overexpression, purification, and characterization of a polyextremophilic β-galactosidase from the Antarctic haloarchaeon Halorubrum luscombofundi. BMC Biotechnol 2013, 13:33.

28. Ng WW, Kennedy SP, Mahairas GG, Bergquist B, Pan M, Shukla HD, Lasky SR, Baliga NS, Thorsson V, Sirogona J, Szwartsiell S, Weir D, Dahl TA, Weitl R, Goo YA, Leithauser B, Keller K, Cruz R, Danzon MJ, Hough DW, Maddocks DG, Jablonski PE, Krebs MP, Angevine CM, Dale H, Xenaberger TA, Peck RF, Pohlschroeder M, Spudich JL, et al: Genome sequence of Halobacterium species NRC-1. Proc Natl Acad Sci U S A 2000, 97:12176–12181.

29. Kennedy SP, Ng WW, Saltzberg SL, Hood L, DasSarma S: Understanding the adaptation of Halobacterium species NRC-1 to its extreme environment through computational analysis of its genome sequence. Genome Res 2001, 11:1641–1650.

30. Coker JA, DasSarma P, Kumar J, Müller JA, DasSarma S: Transcriptional profiling of the model Archeon Halobacterium sp. NRC-1: responses to changes in salinity and temperature. Saline Syst 2007, 3:6.

31. Karan R, DasSarma P, Balcer-Kubickez E, Weng RR, Liao CC, Goodlett DR, Ng WW, DasSarma S: Bioengineering radioresistance by overproduction of RPA, a mammalian-type single-stranded DNA binding protein, in a halophilic archaeon. Appl Microbiol Biotechnol 2013. doi:10.1007/s00253-013-5366-x.

32. Englert C, Pfeifer F: Analysis of gas vesicle gene expression in Halorubrum mediterranei reveals that GvpA and GvpC are both gas vesicle structural proteins. J Biol Chem 1993, 268:9329–9336.

33. Damerval T, Castets AM, Guglielmi G, Hournard J, Tandeau de Marsac N: Occurrence and distribution of gas vesicle genes among cyanobacteria. J Bacteriol 1989, 171:1445–1452.

34. Kinsman R, Walsby AE, Hayes PK: GvpCs with reduced numbers of repeating sequence elements bind to and strengthen cyanobacterial gas vesicles. Mol Microbiol 1995, 17:147–154.

35. DasSarma S, Halladay JT, Jones KG, Donovan AW, Giannasca PJ, de Marsac NT: High-frequency mutations in a plasmid-encoded gas vesicle gene in Halobacterium halobium. Proc Natl Acad Sci U S A 1988, 85:6861–6865.

36. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248–254.

37. DasSarma S, Robb FT, Place AR, Sowers KR, Schreier HI, Fleischmann EM: Archaea: a laboratory manual – halophiles. New York: Cold Spring Harbor Laboratory Press; 1995.

38. Spurr AR: A low viscosity epoxy resin embedding medium for electron microscopy. J Ultrastr Res 1969, 26:31–43.

39. Sato T: A modified method for lead staining of thin sections. J Electron Microsc 1967, 16:133.

0.750